counterion content raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Peptide purity specifications describe which tests define an acceptable lot and how results are reported. A certificate of analysis commonly lists a reverse-phase HPLC purity value, a mass spectrometry identity result, water content, counterion content, and residual solvent data. The specification may set a minimum area percent, such as 95% or 98%, depending on the intended use and grade. No universal threshold applies to all peptides, because sequence length, hydrophobicity, and manufacturing route influence achievable purity.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Peptide purity testing sits within a broader quality control framework. Release testing commonly includes appearance, identity, purity, peptide content, counterion content, water content, and residual solvents. Elemental impurities and microbiological attributes may be examined when relevant to the manufacturing route. Pharmacopoeial monographs and general chapters provide methods and acceptance criteria for some peptides, but many research-grade materials are not covered by such standards. Method validation establishes specificity, linearity, accuracy, precision, range, and robustness for each test.
Handling practices strongly affect measured purity and sample integrity. Many peptides are hygroscopic, susceptible to oxidation, or prone to adsorption on glass and plastic surfaces. Lyophilized powders are typically stored desiccated at -20 °C or below, while solutions may require colder storage and minimized freeze-thaw cycles. Peptides containing cysteine, methionine, or tryptophan can degrade through oxidation or disulfide exchange. Working aliquots reduce repeated exposure to moisture and temperature fluctuations during routine analysis.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95% or 98% area by RP-HPLC | Grade and application dependent |
| Common identity test | Electrospray ionization mass spectrometry | Confirms molecular mass |
| Typical water content method | Karl Fischer titration | Reports residual moisture |
| Common counterion test | Ion chromatography | Detects trifluoroacetate or acetate |
| Typical validation elements | Specificity, linearity, precision, accuracy | Follows method-validation guidance |
Storage and handling conditions affect both peptide stability and the accuracy of later purity tests. Lyophilized powders are commonly kept desiccated at -20 °C or below, while reconstituted solutions require a defined buffer, pH, and temperature range. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis over time. Each cycle may alter the chromatogram and complicate comparison with earlier results. Stability data, when available, should guide handling intervals and solvent choice.
Independent verification is used when a supplier result needs confirmation or when a material supports regulated work. A second laboratory can repeat reverse-phase HPLC and mass spectrometry on the same sample. Discrepancies may arise from different columns, gradients, detection wavelengths, or sample preparation. Moisture uptake and counterion content can lower net peptide mass without changing area percent. Documentation of methods and raw data helps distinguish analytical variation from a true quality difference.
Handling practices influence measured purity. Peptides may adsorb to plastic or glass surfaces, particularly when hydrophobic or positively charged. Weighing hygroscopic powders can introduce water and alter concentration. Dissolving in appropriate solvents and using low-binding tubes can reduce losses. Each laboratory should validate its own procedures because recovery and stability vary with peptide sequence, formulation, and container material. Open questions remain about how best to standardize stability reporting across different peptide classes.
Purity results are only meaningful when linked to a defined sample and method. A certificate of analysis typically lists the analytical technique, column type, gradient, detection wavelength, and integration parameters. It may also report mass confirmation, water content, and counterion composition. For research peptides, laboratories often request the raw chromatogram rather than only a summary percentage. This allows independent review of baseline, peak shape, and any unresolved shoulders that might be missed by a single number.
Stability testing examines how purity changes under controlled conditions. Samples are stored at defined temperatures, such as -20 °C or -80 °C, and analyzed at intervals. Lyophilized powders are generally more stable than solutions because water promotes hydrolysis and aggregation. Repeated freeze-thaw cycles can also degrade peptides, especially those with oxidation-prone residues. Accelerated studies at elevated temperature provide useful comparisons, but they do not always predict long-term behavior at lower temperatures.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
Impurity profiles can include deletion peptides, oxidized forms, truncated sequences, and residual solvents. Some impurities arise during synthesis, cleavage, or purification, while others form during storage. Purity testing often focuses on peptide-related impurities, whereas residual solvents and counterions require separate assays. The significance of a given impurity depends on its amount and properties, which may not be established for a research peptide. Reporting an impurity profile is more informative than reporting a single purity number.
== Structure == CDPSs don’t have a specific structure, given each one has its own specific function, but they still have common architectures, such as a Rossmann-fold domain. CDPSs are monomers that have been found to display a strong structural similarity to the catalytic domains of class Ic aminoacyl tRNA synthetases: both these families, CDPSs and class Ic aaRSs, have a Rossmann-fold domain and their structures can be superimposed showing many structural analogies. CDPSs characteristically feature a deep surface-accessible pocket bordered by the catalytic residues, which is where the catalysis of amide bond formation takes place. This structure is positioned similarly to the aminoacyl binding pocket in aaRSs, which leads to thinking that CDPSs evolved from class Ic aaRSs. CDPSs and aaRSs present substantial differences though, such as the absence of ATP-binding motifs in CDPSs, given that these use, unlike aaRSs, amino acids that have already been activated.
Buprenorphine/naloxone, sold under the brand name Suboxone among others, is a fixed-dose combination medication that includes buprenorphine and naloxone. It is used to treat opioid use disorder, and reduces the mortality of opioid use disorder by 50% (by reducing the risk of overdose on full-agonist opioids such as heroin or fentanyl). It relieves cravings to use and withdrawal symptoms. Buprenorphine/naloxone is available for use in two different forms, under the tongue or in the cheek. Side effects may include respiratory depression (decreased breathing), small pupils, sleepiness, and low blood pressure. The risk of overdose with buprenorphine/naloxone (unless combined with other sedating substances) is exceedingly low, and lower than with methadone, but people are more likely to stop treatment on buprenorphine/naloxone than methadone. Buprenorphine (like methadone) is a treatment option during pregnancy. At lower doses, buprenorphine results in the usual opioid effects; high doses beyond a certain level do not result in greater effects. This is believed to result in a lower risk of overdose than some other opioids. Naloxone is an opioid antagonist that competes with and blocks the effect of other opioids (including buprenorphine) if given by injection. Naloxone is poorly absorbed when taken by mouth and is added to decrease the risk that people will misuse the medication by dissolving the medication and injecting it.
Although there was no patent on the compound, the provisions of the Waxman-Hatch Act gave Bristol-Myers Squibb five years exclusive marketing rights. In 1990, BMS applied to trademark the name taxol as Taxol(R). This was controversially approved in 1992. At the same time, paclitaxel replaced taxol as the generic (INN) name of the compound. Critics, including the journal Nature, argued the name taxol had been used for more than two decades and in more than 600 scientific articles and suggested the trademark should not have been awarded and the BMS should renounce its rights to it. BMS argued changing the name would cause confusion among oncologists and possibly endanger the health of patients. BMS has continued to defend its rights to the name in the courts. BMS has also been criticized for misrepresentation by Goodman and Walsh, who quote from a company report saying "It was not until 1971 that ... testing ... enabled the isolation of paclitaxel, initially described as 'compound 17". This quote is, strictly speaking, accurate: the objection seems to be that this misleadingly neglects to explain that it was the scientist doing the isolation who named the compound taxol and it was not referred to in any other way for more than twenty years. Annual sales peaked in 2000 (the same year that several of BMS's Taxol patents were invalidated via legal challenge from generic manufacturers), reaching US$1.6 billion; paclitaxel became available in generic form in 2000.
Sources: en.wikipedia.org
== History == Tiagabine was discovered at Novo Nordisk in Denmark in 1988 by a team of medicinal chemists and pharmacologists under the general direction of Claus Bræstrup. The drug was co-developed with Abbott Laboratories, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company. It was approved for treatment of epilepsy in the United States in September 1997. In 2005, a bolded warning was added to the labeling of tiagabine by the United States Food and Drug Administration cautioning about association of new-onset seizures in people without epilepsy and discouraging off-label use. Tiagabine was previously subject to Risk Evaluation and Mitigation Strategies (REMS) in the United States, which was instituted in 2010. However, this requirement was eliminated in 2012. United States patents on tiagabine listed in the Orange Book expired in April 2016.
== Medical uses == Metenolone, as its esters, is used almost exclusively in the treatment of anemia due to bone marrow failure. It has also been used to treat wasting syndromes due to major surgery, infection, long-term corticosteroid therapy, malnutrition, or other causes. It has also been used to treat osteoporosis and sarcopenia, to inhibit the natural loss of muscle mass with aging, and to promote weight gain in underweight premature infants and children.
The former Trump Plaza hotel in Atlantic City, New Jersey is demolished in a controlled implosion. The U.S. Food and Drug Administration approves the Patient Specific Talus Spacer 3D-printed talus implant for humanitarian use. The Patient Specific Talus Spacer is the first in the world and first-of-its-kind implant to replace the talus—the bone in the ankle joint. February 18 – NASA successfully lands its Perseverance rover on Mars, seven months after launching. February 19 – The U.S. officially rejoins the Paris Agreement, 107 days after leaving. February 22 New York Rangers winger Artemi Panarin takes a personal leave of absence after the Russian tabloid Komsomolskaya Pravda publishes a story in which former Kontinental Hockey League coach Andrei Nazarov accuses him of sexually assaulting an 18-year old Latvian woman in Riga. The team releases a statement calling the allegations against Panarin an "intimidation tactic" against him after speaking out against "recent political events", most notably expressing his support for Russian opposition leader Alexei Navalny, who was detained upon return to Russia from Germany. Enabling legislation for New Jersey Public Question 1 is signed into law by governor Phil Murphy, making New Jersey the 14th state to legalize recreational cannabis. The Supreme Court rejects a last-ditch attempt by Donald Trump to shield his financial records, and issues an order requiring his accountants to turn over his tax and other records to prosecutors in New York.
=== Industrial inorganic chemistry === Inorganic chemistry is a highly practical area of science. Traditionally, the scale of a nation's economy could be evaluated by their productivity of sulfuric acid. An important man-made inorganic compound is ammonium nitrate, used for fertilization. The ammonia is produced through the Haber process. Nitric acid is prepared from the ammonia by oxidation. Another large-scale inorganic material is portland cement. Inorganic compounds are used as catalysts such as vanadium(V) oxide for the oxidation of sulfur dioxide and titanium(III) chloride for the polymerization of alkenes. Many inorganic compounds are used as reagents in organic chemistry such as lithium aluminium hydride.
Sources: en.wikipedia.org
== Research == Acetylcysteine is under preliminary research for its potential to treat androgenetic alopecia (male baldness), with or without adjacent treatments such as with minoxidil. Acetylcysteine may have otoprotective properties and could be useful for preventing hearing loss and tinnitus in some cases. Acetylcysteine may be an adjunct therapy for the treatment of addiction to cocaine, nicotine, alcohol, and other drugs.
=== Legal status === In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis. In January 2022, the US Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.
The broadcast pattern covered an area of about 100 degrees in a roughly fan-shaped area, with a smaller side lobe to the rear, courtesy of the reflectors, and much smaller ones to the sides. When the signal reflected off the ground it underwent a ½ wavelength phase-change, which caused it to interfere with the direct signal. The result was a series of vertically stacked lobes about 5 degrees wide from 1 degree off the ground to the vertical. The system was later expanded by adding another set of four additional antennas closer to the ground, wired in a similar fashion. The receiver consisted of an Adcock array consisting of four 240 foot (73 m) tall wooden towers arranged at the corners of a square. Each tower had three sets (originally two) of receiver antennas, one at 45, 95 and 215 feet off the ground. The mean height of the transmitter stack was 215 feet, which is why the topmost antenna was positioned at the same altitude in order to produce a reception pattern that was identical to the transmission. A set of motor-driven mechanical switches allowed the operator to select which antenna was active. The output of the selected antenna on each of the four towers was sent to a single radiogoniometer system (not Watt's own huff-duff solution). By connecting the antennas together in X-Y pairs the horizontal bearing could be measured, while connecting together the upper and lower antennas allowed the same goniometer to be used to measure the vertical angle. Two physical layout plans were used, either 'East Coast' or 'West Coast'.
Independent Order of Sons of Abraham - Founded in 1892 by a group of Jewish men who were already members of the Masons, Sons of Benjamin, and the Order of B'rith Abraham. Membership in 1899 almost exclusively in New York and Brooklyn, numbered about 2,400 divided equally between men and women. Independent Order of Sons of Benjamin - Founded in 1877 in New York by a group of men who were already members of the Brith Abraham. By 1899 it had spread to the "principal cities of the United States and the Dominion of Canada." It authorized the creation of female lodges, of which there were about 20 in 1899. In 1899 there were about 18,000 male members and 2,500 women. In 1918 it had 800 members in 25 lodges, of which 450 were located in New York City with 18 lodges. Its headquarters in 1918 were at 953 Third Avenue. Offered the "usual secret society forms, and privileges". The emblem was a triangle between the letters F and P with an L under it. Offered insurance against death under the Metropolitan Life Insurance Company. Independent Western Star Order - Founded in 1894. The Eastern Division was headquartered at 40 Rivington Street. Had 21,000 members in 1918, with 2000 members in 24 lodges in New York City. Offered accident, death, and burial insurance May or may not be related to an order of the same name operating out of Chicago. Independent Workmens Circle - Founded in 1906 in Boston. Open to working men and women and "those in sympathy with the cause of labor". In 1923 had 77 lodges with 5,726 benefit members. Headquarters 86 Leverett Street, Boston.
=== Surgical anatomy for nasal reconstruction === The human nose is a sensory organ that is structurally composed of three types of tissue: (i) an osseo-cartilaginous support framework (nasal skeleton), (ii) a mucous membrane lining, and (iii) an external skin. The anatomic topography of the human nose is a graceful blend of convexities, curves, and depressions, the contours of which show the underlying shape of the nasal skeleton. Hence, these anatomic characteristics permit dividing the nose into nasal subunits: (i) the midline (ii) the nose-tip, (iii) the dorsum, (iv) the soft triangles, (v) the alar lobules, and (vi) the lateral walls. Surgically, the borders of the nasal subunits are ideal locations for the scars, whereby is produced a superior aesthetic outcome, a corrected nose with corresponding skin colors and skin textures.
Sources: en.wikipedia.org
Purity percentages vary because each laboratory uses its own column, mobile phase, gradient, detection wavelength, and integration settings. A 95% value from one method may not equal 95% from another method. Comparative assessment requires the same validated procedure or an orthogonal cross-check.
A useful certificate of analysis states the peptide sequence, lot number, test methods, acceptance criteria, and measured results. It typically reports HPLC purity, mass spectrometry identity, water content, counterion content, and residual solvents when relevant. The document should also include a chromatogram and the date of testing.
Higher HPLC purity reduces the relative amount of ultraviolet-detectable impurities, but it does not guarantee correct sequence, stereochemistry, or biological activity. Some impurities may be invisible to the chosen method, and aggregates or counterions may still be present. Fitness for purpose depends on the intended application and the full set of tests.
Lyophilized peptides are generally stored desiccated at -20 °C or lower, protected from light and moisture. Solutions are often kept at -80 °C in aliquots to limit freeze-thaw damage. Specific sequences may require different conditions based on oxidation or aggregation risk.